Novo Nordisk’s obesity drug Wegovy cleared to treat MASH

August 15, 2025

•

1 min read

•

statnews.com

The FDA granted accelerated approval to Wegovy for patients with metabolic dysfunction-associated steatohepatitis.

Elaine Chen covers biotech, co-writes The Readout newsletter , and co-hosts STAT’s weekly biotech podcast, The Readout Loud . You can reach Elaine on Signal at elaineywchen.70. Novo Nordisk’s obesity drug Wegovy was cleared by U.S. regulators on Frid... [739 chars]

Read Original Article

Source: statnews.com

Visit Source

Share this article

Twitter Facebook

Back to business news